Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5765 in Healthy Subjects
NCT07551167Phase 1Recruiting
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing HRS-5765 group with HRS-5765 placebo group (2 arms). Primary endpoints: Incidence of adverse events and Incidence of serious adverse events. Started May 2026; status: recruiting.
02
Drugs
HRS-5765
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07551167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551167.